AR076864A1 - Procedimiento y composicion para mejorar la absorcion de agentes terapeuticos - Google Patents

Procedimiento y composicion para mejorar la absorcion de agentes terapeuticos

Info

Publication number
AR076864A1
AR076864A1 ARP100101627A ARP100101627A AR076864A1 AR 076864 A1 AR076864 A1 AR 076864A1 AR P100101627 A ARP100101627 A AR P100101627A AR P100101627 A ARP100101627 A AR P100101627A AR 076864 A1 AR076864 A1 AR 076864A1
Authority
AR
Argentina
Prior art keywords
mixture
active ingredient
aspirin
dissolution aid
tablet
Prior art date
Application number
ARP100101627A
Other languages
English (en)
Inventor
Julin Tong
Stephanie Petaway-Hickson
Eric R First
Ashish B Patel
Guido Schmitz
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43062708&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR076864(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of AR076864A1 publication Critical patent/AR076864A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds

Abstract

Reivindicacion 1: Una mezcla para moldear en un comprimido farmacéutico que comprende cristales de un ingrediente medicinalmente activo que tiene un tamano de partícula inferior a aproximadamente 40 mm y un coadyuvante de disolucion, habiéndose molido dicha mezcla suficientemente hasta recubrir sustancialmente dichos cristales con dicho coadyuvante de disolucion, con lo cual se mejora la velocidad de disolucion de dicho ingrediente medicinalmente activo cuando está moldeado en forma de comprimido en comparacion con la velocidad de disolucion de dicho ingrediente activo en forma de comprimido sin tal molienda. Reivindicacion 6: La mezcla de la reivindicacion 5, en la que dicho coadyuvante de disolucion está seleccionado del grupo constituido por sales de sodio, calcio, u magnesio y potasio de carbonatos y bicarbonatos. Reivindicacion 7: La mezcla de la reivindicacion 1, en la que dicho ingrediente medicinalmente activo comprende aspirina y dicho coadyuvante de disolucion se selecciona del grupo constituido por sales de sodio y calcio de carbonatos y bicarbonatos. Reivindicacion 8: La mezcla de la reivindicacion 7, en la que dicha mezcla comprende de aproximadamente 37 mg a aproximadamente 500 mg de aspirina, y dicho coadyuvante de disolucion comprende de aproximadamente el 5% a aproximadamente el 40% en peso de aspirina presente en dicha mezcla.
ARP100101627A 2009-05-11 2010-05-11 Procedimiento y composicion para mejorar la absorcion de agentes terapeuticos AR076864A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12/387,977 US11135188B2 (en) 2009-05-11 2009-05-11 Method and composition to improve absorption of therapeutic agents

Publications (1)

Publication Number Publication Date
AR076864A1 true AR076864A1 (es) 2011-07-13

Family

ID=43062708

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100101627A AR076864A1 (es) 2009-05-11 2010-05-11 Procedimiento y composicion para mejorar la absorcion de agentes terapeuticos

Country Status (15)

Country Link
US (1) US11135188B2 (es)
EP (1) EP2429502B1 (es)
AR (1) AR076864A1 (es)
BR (1) BRPI1013509A2 (es)
CA (1) CA2761678A1 (es)
CL (1) CL2011002807A1 (es)
CO (1) CO6460753A2 (es)
EA (1) EA201171399A1 (es)
HU (1) HUE043173T2 (es)
MX (1) MX2011011928A (es)
PL (1) PL2429502T3 (es)
PT (1) PT2429502T (es)
SI (1) SI2429502T1 (es)
UY (1) UY32624A (es)
WO (1) WO2010132095A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11135188B2 (en) 2009-05-11 2021-10-05 Bayer Healthcare Llc Method and composition to improve absorption of therapeutic agents
EP2953617B1 (en) * 2013-02-06 2019-10-02 Hermes Arzneimittel GmbH Pharmaceutical compositions incorporating low-dose drugs
WO2015023675A2 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
PL3154528T3 (pl) 2014-06-11 2023-07-10 SpecGx LLC Suszone rozpyłowo kompozycje o różnych profilach rozpuszczania i sposoby ich wytwarzania
WO2016010771A1 (en) 2014-07-17 2016-01-21 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
JP2017531026A (ja) 2014-10-20 2017-10-19 ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド 徐放性乱用抑止性液体充填剤形
US11197830B2 (en) * 2019-02-27 2021-12-14 Aft Pharmaceuticals Limited Pharmaceutical composition containing acetaminophen and ibuprofen
EP4243781A1 (en) * 2020-11-13 2023-09-20 Bayer HealthCare, LLC Oral bilayer tablets comprising acetylsalicylic acid and pseudoephedrine, methods of preparing and using thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB191225486A (en) 1912-11-06 1913-04-24 Herbert Sefton-Jones Manufacture and Production of Improved Pharmaceutical Preparations.
US2293359A (en) 1941-01-08 1942-08-18 Quisling Sverre Acetyl salicylic acid preparation
FI89004C (fi) 1988-02-16 1993-08-10 Pertti J Neuvonen Anvaendning av tillsatsmedel foer oekning av absorptionshastigheten av laekemedel i orala laekemedelspreparat
RU2099058C1 (ru) 1992-06-15 1997-12-20 Институт химии твердого тела и переработки минерального сырья СО РАН Способ получения твердой быстрорастворимой дисперсной системы, содержащей ацетилсалициловую кислоту
US5665388A (en) 1995-11-13 1997-09-09 Health Corporation Method for preparation of an alkaline and aspirin combination compound
NZ502990A (en) 1997-08-27 2002-02-01 Hexal Ag Pharmaceutical compositions of meloxicam with improved solubility and bioavailability
US8231899B2 (en) * 1998-09-10 2012-07-31 Nycomed Danmark Aps Quick release pharmaceutical compositions of drug substances
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
RU2170582C1 (ru) 2000-02-17 2001-07-20 Институт химии твердого тела и механохимии СО РАН Способ получения быстрорастворимой таблетированной формы ацетилсалициловой кислоты
CA2565941A1 (en) 2004-05-04 2005-11-10 Equitech Corporation Improved nsaid composition
US8216610B2 (en) 2004-05-28 2012-07-10 Imaginot Pty Ltd. Oral paracetamol formulations
EA200971133A1 (ru) * 2004-06-29 2010-10-29 Никомед Данмарк Апс Производство фармацевтических композиций с быстрым высвобождением на основе водонерастворимых лекарственных средств и фармацевтические композиции, получаемые способом по изобретению
CA2584957C (en) * 2004-10-21 2015-08-25 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
CA2629904C (en) 2005-11-28 2018-07-10 Imaginot Pty Ltd. Oral therapeutic compound delivery system
US11135188B2 (en) 2009-05-11 2021-10-05 Bayer Healthcare Llc Method and composition to improve absorption of therapeutic agents

Also Published As

Publication number Publication date
CL2011002807A1 (es) 2012-06-15
HUE043173T2 (hu) 2019-08-28
MX2011011928A (es) 2011-12-06
PT2429502T (pt) 2019-03-29
CO6460753A2 (es) 2012-06-15
BRPI1013509A2 (pt) 2016-04-05
SI2429502T1 (sl) 2019-05-31
WO2010132095A1 (en) 2010-11-18
EP2429502B1 (en) 2018-12-26
UY32624A (es) 2010-12-31
EP2429502A1 (en) 2012-03-21
US20100286100A1 (en) 2010-11-11
US11135188B2 (en) 2021-10-05
EA201171399A1 (ru) 2012-05-30
CA2761678A1 (en) 2010-11-18
PL2429502T3 (pl) 2019-07-31
EP2429502A4 (en) 2012-10-24
WO2010132095A8 (en) 2011-07-07

Similar Documents

Publication Publication Date Title
AR076864A1 (es) Procedimiento y composicion para mejorar la absorcion de agentes terapeuticos
PE20091184A1 (es) Formas de dosificacion farmaceutica
WO2013101897A3 (en) Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
CO6630134A2 (es) Formulación orales y sales lipofílicas de metilnaltrexona
JP2014218522A5 (es)
RU2015124694A (ru) Саморегулируемое высвобождение фармацевтического ингредиента
CR11625A (es) Formulacion de capsula
NZ590291A (en) Pharmaceutical compositions for treatment of parkinson's disease
ES2916649T1 (es) Composiciones y usos para el tratamiento de la esclerosis múltiple
AR075735A1 (es) Composiciones farmaceuticas de liberacion inmediata que comprenden oxicodona y naloxona. uso
ES2572157T3 (es) Composiciones en forma de partículas para la administración de fármacos poco solubles
WO2012005500A3 (ko) 다폭세틴을 포함하는 시간차 서방출 경구투여형 약학적 조성물
WO2008084504A3 (en) Pharmaceutical compositions of angiotensin ii receptor blockers
PE20141539A1 (es) Una nueva composicion terapeutica que contiene apomorfina como principio activo
AR077546A1 (es) Formulaciones de comprimidos de 3-cianoquinolina y usos de los mismos
AR095159A2 (es) Una composición farmacéutica en forma de cápsula para administración oral
TN2015000135A1 (en) Modified release formulations for oprozomib
PE20130403A1 (es) Comprimido de desintegracion via oral que contiene acarbosa
EA201270573A1 (ru) Гранулированный в расплаве цинакальцет
TN2014000031A1 (en) Use of organic compound for the treatment of noonan syndrome
BR112014004732A2 (pt) composto benzotiazolona
BR112015019776A2 (pt) comprimidos de duplo uso oral em composições farmacêuticas de sais de sulfato e métodos de uso dos comprimidos
JP2013521297A5 (es)
PE20061352A1 (es) Composicion farmaceutica que comprende valopicitabina (val-mcyd)
ECSP11010998A (es) Formulación galénica que comprende alisquireno y proceso para su preparación mediante granulación de extrusión fundida

Legal Events

Date Code Title Description
FB Suspension of granting procedure